ChromaDex Corporation (CDXC)
CDXC moved a median of +0.80% 30 minutes after news, and 0.00% by the close. How CDXC actually reacts to news — the realized, point-in-time move the market made, measured across 118 labeled events over the last three years with zero look-ahead.
CDXC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 103 |
| 30-min | +0.80% | 61% | 104 |
| 60-min | +0.71% | 59% | 104 |
| to close | 0.00% | 47% | 104 |
| Middle 50% of CDXC reactions | -0.80% to +2.06% |
|---|---|
| Median reaction (30-min) | +0.80% |
| Measured reactions | 118 |
Half of all ChromaDex Corporation news events land between -0.80% and +2.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CDXC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CDXC's baseline. Nothing else.
Recent CDXC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Niagen Bioscience, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Niagen Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Niagen Bioscience, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS Niagen Bioscience, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A Niagen Bioscience, Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form DEFA14A Niagen Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 8-K Niagen Bioscience, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 | Press release | Business Wire | -0.46% | +0.26% | |
| ChromaDex to Present at the 37th Annual Roth Conference | Press release | Business Wire | +0.64% | +0.00% | |
| ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results | Press release | Business Wire | +12.08% | +27.42% | |
| Form 10-K ChromaDex Corp. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +12.08% | +27.42% | |
| Form 8-K ChromaDex Corp. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +12.08% | +27.42% | |
| Form 8-K ChromaDex Corp. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +3.87% | |
| ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025 | Press release | Business Wire | +1.61% | +3.85% | |
| ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 | Press release | Business Wire | -0.18% | -3.93% | |
| Form 8-K ChromaDex Corp. For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | -0.41% | -2.28% | |
| Form 8-K ChromaDex Corp. For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | -10.60% | |
| ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category | Press release | Business Wire | +1.61% | +2.29% | |
| Form 8-K ChromaDex Corp. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | -0.80% | |
| ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement | Press release | Business Wire | -0.71% | +2.27% | |
| ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide | Press release | Business Wire | -1.51% | -2.73% | |
| ChromaDex Corporation Reports Third Quarter 2024 Financial Results | Press release | Business Wire | +2.83% | +42.93% | |
| Form 10-Q ChromaDex Corp. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.83% | +42.93% | |
| Form 8-K ChromaDex Corp. For: Oct 31 | SEC filing · Form 8-K | SEC EDGAR | +2.83% | +42.93% | |
| ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 | Press release | Business Wire | +1.43% | +4.56% | |
| ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 | Press release | Business Wire | +0.00% | -1.15% | |
| ChromaDex to Participate in the 17th Annual LD Micro Main Event | Press release | Business Wire | -0.58% | +0.00% | |
| Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) | Press release | Business Wire | +0.00% | -1.18% | |
| Form 8-K ChromaDex Corp. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +0.85% | -3.67% | |
| ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference | Press release | Business Wire | +0.00% | -1.30% | |
| ChromaDex Appoints Ozan Pamir as Chief Financial Officer | Press release | Business Wire | -2.55% | -2.42% | |
| Form 8-K ChromaDex Corp. For: Sep 19 | SEC filing · Form 8-K | SEC EDGAR | -2.55% | -2.42% | |
| ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics | Press release | Business Wire | +0.59% | -2.07% | |
| ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions | Press release | Business Wire | -0.59% | +0.30% | |
| ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 | Press release | Business Wire | +1.21% | +6.04% | |
| ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ | Press release | Business Wire | -1.19% | -2.39% | |
| ChromaDex Corporation Reports Second Quarter 2024 Financial Results | Press release | Business Wire | -7.12% | -2.37% | |
| Form 10-Q ChromaDex Corp. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.12% | -2.37% | |
| Form 8-K ChromaDex Corp. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -7.12% | -2.37% | |
| ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference | Press release | Business Wire | -1.94% | +4.26% | |
| ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 | Press release | Business Wire | -1.64% | +4.92% | |
| ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) | Press release | Business Wire | -0.34% | +3.02% | |
| ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel | Press release | Business Wire | +1.07% | +5.69% | |
| ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August | Press release | Business Wire | +0.90% | +10.04% | |
| Form 8-K ChromaDex Corp. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | -3.64% | |
| ChromaDex to Join Russell 2000® Index | Press release | Business Wire | -0.72% | -2.89% | |
| Form 8-K ChromaDex Corp. For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +9.88% | |
| Form 8-K ChromaDex Corp. For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +4.20% | -2.40% | |
| Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) | Press release | Business Wire | +0.36% | -7.27% | |
| ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) | Press release | Business Wire | +4.88% | +1.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CDXC section they belong to.
Where else CDXC is measured.
CDXC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| HEMP NATURALS INC (HPMM) | 120 | 0.00% | 37% |
| Marker Therapeutics, Inc. (MRKR) | 120 | -0.23% | 39% |
| ADHERA THERAPEUTICS INC (ATRX) | 117 | 0.00% | 23% |
| MediciNova, Inc. (MNOV) | 117 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ChromaDex Corporation's median reaction calculated?
Every labeled CDXC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 118 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 61% of CDXC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CDXC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.